Two Years Experience of Daily Self-Administered Subcutaneous Erythropoietin
| Autor: | B. Branger, B. Nonnast-Daniel, M. Pollok, Stanley Shaldon, G. Deschodt, C. Granolleras |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Injections Subcutaneous Self Administration law.invention Renal Dialysis law hemic and lymphatic diseases medicine Humans Erythropoietin Injections subcutaneous Aged business.industry Hematology General Medicine Middle Aged Recombinant Proteins Surgery Subcutaneous route Nephrology Anesthesia Recombinant DNA Kidney Failure Chronic Female Self-administration business medicine.drug |
| Zdroj: | Blood Purification. 8:268-271 |
| ISSN: | 1421-9735 0253-5068 |
| DOI: | 10.1159/000169977 |
| Popis: | Recombinant human erythropoietin (EPO) has been used for 4 years in end-stage renal disease patients, administered intravenously 3 times a week. A study was undertaken to determine the optimal way of administration comparing 3 times weekly intravenous EPO to self-administered daily subcutaneous EPO (SADSCEPO). In a first group of 4 patients, we demonstrated that the change from 3 times weekly intravenous EPO to SADSCEPO permitted a dose reduction of 70%. In a second group of 20 patients who started the EPO therapy with the daily subcutaneous route at a median dose of 12 U/kg/day, the hematocrit increased from 20 to 30% in 4 months and remained over 30% in spite of a median dose reduction to 9 U/kg/day. The patients' acceptance of SADSCEPO was good. The mechanism allowing such a dose reduction is unknown. However, the significant reduction in median dosage requirement with the subcutaneous route should allow a greater number of patients to be treated more cost-effectively. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|